Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atul Patel

Neurological Surgery Fairfield, CA Medical Doctor

NPI 1740321884 CMS profile 78672

1200 B Gale Wilson Blvd, Ste A, Fairfield, CA 94533

Open in the dashboard

General payments

$95,712

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Atul Patel of Fairfield, CA is reported in the CMS Open Payments database as having received $95,712 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,400 38
2024 General $1,934 31
2023 General $3,115 38
2022 General $16,144 44
2021 General $4,541 23
2020 General $269 6
2019 General $42,309 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atul Patel
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Atul Patel were reported at $27,400. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Atul Patel Neurological Surgery median Middle half National median
2019 $42,309 $582 $138–$3,006 $163
2020 $269 $294 $76–$2,174 $114
2021 $4,541 $387 $105–$2,432 $132
2022 $16,144 $542 $139–$2,989 $149
2023 $3,115 $534 $145–$2,697 $160
2024 $1,934 $574 $155–$3,046 $164
2025 $27,400 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spineart USA Inc $90,601 109 payments
  2. Spineart SA $1,868 6 payments
  3. Alphatec Spine, Inc $459 11 payments
  4. Spineology Inc. $356 2 payments
  5. Integra LifeSciences Corporation $215 11 payments
  6. Neurocrine Biosciences, Inc. $187 6 payments
  7. Orthofix Medical, Inc. $185 1 payment
  8. CoreLink, LLC $165 1 payment
  9. Pfizer Inc. $139 5 payments
  10. AbbVie, Inc. $131 4 payments
  11. Other $1,406 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $49,500 10 payments
  2. Travel and Lodging $34,454 12 payments
  3. Food and Beverage $11,714 194 payments
  4. Gift $44 1 payment
Products named General payments · program years 2019–2025
  1. JULIET TL Ti $12,500 1 payment
  2. PERLA TL Orthopedic $6,764 22 payments
  3. ROMEO MIS $1,154 2 payments
  4. JULIET LL - LATERAL CAGE PEEK $762 2 payments
  5. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $356 2 payments
  6. PERLA TL MIS $300 5 payments
  7. Cure ACP $296 4 payments
  8. SCARLET AL-T $289 2 payments
  9. PERLA C $278 6 payments
  10. Perla TL Orthopedic $257 5 payments
  11. Other $4,598 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$163,169

Medicare's payments for the services billed

Medicare patients

217

Average age 73

Services billed

516

132 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 36%
Chronic kidney disease 28%
Depression 26%
Ischemic heart disease 24%
Osteoporosis 22%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $105
$105 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $61
$61 — —
Leqembi
  • Eisai Inc. $18
$18 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $16
$16 — —
OCTAGAM IMMUNE GLOBULIN (HUMAN)
  • PFIZER INC. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record